https://twitter.com/nephondemand/status/1723469278014267535@gunnar_heine Indeed. This one trial doesn't knock SGLT2i in my mind. As a physician community, however, we need to know the limits of this class of agents. I'm glad we are uncovering those limits sooner rather than later. #AHA23 Enjoy Philly. We were there last week for #KidneyWk.
— Tejas Desai, MD MBA (@nephondemand) Nov 11, 2023
Saturday, November 11, 2023
@nephondemand
http://twitter.com/nephondemand
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment